BindingDB

The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.4K Targets. Of those, 1.6M data for 748K Compounds and 4.8K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Donate Now

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

Advanced Search

11 articles for JV Prasad

The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
New hydroxyethylamine HIV protease inhibitors that suppress viral replication.EBI
University of Wisconsin-Madison
 
Nonpeptidic HIV protease inhibitors: 3-(S-benzyl substituted)-4-hydroxy-6-(phenyl substituted)-2H-pyran-2-one with an inverse mode of bindingEBI
TBA
 
A topliss tree analysis of the HIV-protease inhibitory activity of 6-phenyl-4-hydroxy-pyran-2-onesEBI
TBA
Antibacterial oxazolidinones possessing a novel C-5 side chain. (5R)-trans-3-[3-Fluoro-4- (1-oxotetrahydrothiopyran-4-yl)phenyl]-2- oxooxazolidine-5-carboxylic acid amide (PF-00422602), a new lead compound.EBI
Pfizer
4-hydroxy-5,6-dihydro-2H-pyran-2-ones.3. Bicyclic and hetero-aromatic ring systems as 3-position scaffolds to bind to S1' and S2' of the HIV-1 protease enzyme.EBI
Warner-Lambert
Pyridyl analogs of 1-(2-cyano-3,12-dioxooleana-1,9(11)dien-28-oyl) imidazoleBDB
Dartmouth College
Cannabinoid-2 agonistsBDB
Allergan
Pteridine ketone derivative and applications thereof as EGFR, BLK, and FLT3 inhibitorBDB
East China University of Science and Technology
Inhibitors of PI3K-delta and methods of their use and manufactureBDB
Exelixis
Combinations comprising PDE 2 inhibitors such as 1-aryl-4-methyl-[1,2,4]triazolo-[4,3-A]]quinoxaline compounds and PDE 10 inhibitors for use in the treatment of neurological of metabolic disordersBDB
Janssen Pharmaceutica
BET bromodomain inhibitors and therapeutic methods using the sameBDB
University of Michigan